Envestnet Portfolio Solutions Inc. Grows Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Envestnet Portfolio Solutions Inc. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,580 shares of the life sciences company’s stock after buying an additional 614 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Illumina were worth $2,082,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Catalyst Funds Management Pty Ltd lifted its stake in shares of Illumina by 1,962.5% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 16,500 shares of the life sciences company’s stock valued at $2,205,000 after buying an additional 15,700 shares in the last quarter. Carret Asset Management LLC purchased a new position in shares of Illumina during the 4th quarter valued at $213,000. Achmea Investment Management B.V. lifted its stake in shares of Illumina by 46.6% during the 4th quarter. Achmea Investment Management B.V. now owns 35,221 shares of the life sciences company’s stock valued at $4,706,000 after buying an additional 11,200 shares in the last quarter. Vestcor Inc increased its holdings in Illumina by 21.9% in the 4th quarter. Vestcor Inc now owns 15,589 shares of the life sciences company’s stock valued at $2,083,000 after acquiring an additional 2,796 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Illumina by 16.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,108 shares of the life sciences company’s stock valued at $148,000 after acquiring an additional 156 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ILMN. Stephens reiterated an “overweight” rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Canaccord Genuity Group decreased their price objective on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. Citigroup cut their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and decreased their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Finally, Guggenheim lowered their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Trading Down 0.2 %

Shares of ILMN opened at $84.79 on Friday. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66. The company has a 50-day moving average of $109.19 and a 200 day moving average of $128.58. The firm has a market capitalization of $13.43 billion, a price-to-earnings ratio of -11.04, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.